Kenneth Bender, PharmD, MA

Its not only shortage of ventilators, but of the sedatives, anesthetics and paralytic agents for patients on ventilators that reveal inadequacies in supply chain.

Although controlled trial results of remdesivir for COVID-19 won't be available for several weeks, early experience with compassionate use is detailed in a new NEJM report.

Loss of smell or taste has been reported to occur with COVID-19 in absence of other symptoms, heightening risk of exposure for unknowing contacts.

Medical sleuths identify potential of baricitinib for COVID-19 by using artificial intelligence to sift through available agents that act on receptors of interest.

Anthony Fauci, MD, of NIAID, Robert Redfield, MD, of CDC, and others considered initial epidemiology from Wuhan China, and the need to obtain, and act on new data.

Ocular exams in a series of patients hospitalized with COVID-19 revealed one-third had conjunctivitis symptoms.

A placebo-controlled trial of hydroxychloroquine in patients hospitalized with COVID-19 finds the drug shortened time to recovery, possibly lessened severity.

The coronavirus pandemic is disrupting clinical trials for multiple diseases, from Alzheimer's to Zika.

New guidelines on COVID-19 from WHO, CDC, and CMS advise long-term care facilities on protecting their elderly, vulnerable populations and staff.

Clinicians are calling for greater preparedness for post acute care of patients who recover from COVID-19

Statistical models forecast the spread of COVID-19 based on pre-pandemic travel from Wuhan, China.

High-dose intravenous immunoglobulin appeared to reverse deteriorating courses of COVID-19 in 3 case reports from Wuhan, China.

Investigations in the US and China make a case for using convalescent plasma, a “last resort” for SARS, as an early treatment for COVID-19.

A Central Science report from the CAS division of the American Chemical Society details developments and recommends directions against COVID-19 pandemic.

New analyses of the novel coronavirus and previously circulating SARS viruses reveal promising immunologic targets for vaccine against COVID-19.

A multifaceted intervention has tripled the rate of hepatitis C virus screening in a baby boomer population.

The first study to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening among pregnant women in the US in the era of direct-acting antiviral (DAA) treatment demonstrates that it would be "highly" cost effective, even in states with low HCV prevalence.

Investigators on a new study found that the media was both complicit in increasing stigma around pre-exposure prophylaxis (PrEP), and helpful in reducing it as an impediment to its use for HIV prevention.

Successful treatment of recently acquired hepatitis C virus infection in 8 weeks, with a regimen currently approved for 12 weeks, could enable shorter, less costly treatment.

Procalcitonin levels can help differentiate bacterial and viral infections but did not influence antibiotic prescribing in hospital emergency departments.

The World Health Organization has a new way to identify cost-effective measures to address the increasing prevalence of drug-resistant HIV in sub-Saharan Africa.